+Hosted content

Head and neck carcinoma is now the sixth most common cancer worldwide¹

Mr Rajan Patel, leading head and neck surgeon at MercyAscot talks about red flag signs and symptoms that may suggest head and neck cancer

Dulaglutide, a once-weekly injectable medicine, will soon be available for second-line treatment of type 2 diabetes. As most people with type 2 diabetes will require an injectable therapy at some stage, it is important to build acceptability early in the patient journey

When clinically indicated, empagliflozin can be started in patients with type 2 diabetes using the steps shown in this resource. Always maintain metformin treatment if tolerated.

Talking points, relevant for all patients starting empagliflozin, are provided along with two algorithms and accompanying prescribing notes. Which algorithm you follow will depend on your patient’s level of hypoglycaemia risk

The effect of ENTRESTO® on physical and social activities compared with enalapril was equivalent to a difference of 9 years of ageing.¹

Diabetes clinical nurse specialist Lisa Sparks discusses the place of empagliflozin and dulaglutide in treatment of type 2 diabetes, with emphasis on potential side effects, sick-day management and improving patient adherence

All patients with heart failure with reduced ejection fraction (HFrEF), regardless of their symptoms have a poor prognosis. Within three years, 34% of patients with mild to moderate heart failure (NYHA class I and II) die¹

Introducing to our valued New Zealand Doctor Rata Aotearoa subscribers, the new Capture button

Over a lifetime, an active person can walk the equivalent distance of five times around the equator!¹

Click here for V-Go^® free trial.

Are you treating your type 2 diabetes patients with insulin and do they still struggle to achieve their HbA1C target? Insulin injections might make patients feel uncomfortable in social circumstances while others are needle phobic, leading to poor compliance and increases in HbA1C